

Aptanomics

[View the current Aptanomics Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/18631-Aptanomics.html>)

Contact Details:

181-203, avenue Jean Jaurès
Lyon

Tel: (33) 4 37 65 55 00
Fax: (33) 4 37 65 06 17
Email: info@aptanomics.com

69007
France

Aptanomics discovers and develops new drugs in major markets of unmet medical need. The Company focuses on well-validated but hard-to-crack therapeutic targets that are involved in signalling pathways that are deregulated in a broad range of cancers. A novel Bcl antagonist and a unique kinase antagonist are currently in development. Aptanomics has made the transition from establishing a robust discovery platform to focusing on the rapid development of its first molecules, which differ from competing products principally because they bind with high specificity to novel, validated sites on intractable targets. The Company's proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. This nourishes its pipeline with a renewable source of product opportunities for in-house development and co-development through partnerships with major pharmaceutical companies. Aptanomics entered into an R&D collaboration with Boehringer Ingelheim in June 2005.

Recent Publications by Aptanomics:



- [Peptide aptamers for small molecule drug discovery.](#)
*Peptide aptamers have primarily been used as research tools to manipulate...*6th May, 2009
Aptanomics S.A., Imaxio, Lyon, France.- *Methods Mol Biol.* 2009;535:373-88. ([DOI Direct Link](#))
- [Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures.](#)
*Peptide aptamers are combinatorial proteins that specifically bind...*29th June, 2007
Aptanomics, 181-203, Avenue Jean Jaures, 69007 Lyon, France.- *Nat Protoc.* 2006;1(3):1066-91. ([DOI Direct Link](#))
- [An antiproliferative genetic screening identifies a peptide aptamer that targets calcineurin and up-regulates its activity.](#)
*Peptide aptamers are combinatorial recognition molecules that consist of a...*5th June, 2007

Aptanomics S.A., 181-203, avenue Jean Jaures, 69007 Lyon, France.- Mol Cell Proteomics. 2007 Mar;6(3):451-9. Epub 2006 Dec 4. ([DOI Direct Link](#))

- [Peptide aptamers as guides for small-molecule drug discovery.](#)
*Peptide aptamers are combinatorial protein reagents that bind to target...*20th January, 2007
 Aptanomics, 181-203 avenue Jean Jaures, 69007 Lyon, France.- Drug Discov Today. 2006 Apr;11(7-8):334-41. ([DOI Direct Link](#))
- [A universal transgene silencing method based on RNA interference.](#)
*Inducible gene expression systems have contributed significantly to the...*28th July, 2004
 Aptanomics and INSERM U412, Ecole Normale Superieure, 46, allée d'Italie,- Nucleic Acids Res. 2004 Jul 12;32(12):e102. ([DOI Direct Link](#))

Press Releases on Aptanomics:

Aptanomics to validate targets and identify new druggable sites for	1st August, 2005	Aptanomics	<i>Aptanomics to validate targets and identify new druggable sites for Boehringer Ingelheim Lyon, France, 1st August 2005 - Boehringer</i>
APTANOMICS COMPLETES FUNDING TO DEVELOP NEW DRUG DISCOVERY PLATFORMS	1st October, 2002	Aptanomics	<i>APTANOMICS COMPLETES FUNDING TO DEVELOP NEW DRUG DISCOVERY PLATFORMS BASED ON PEPTIDE APTAMERS Lyon, France, 28 October 2002 Aptanomics announced today</i>
European Biotechnology Crossroads presents international conference	1st January, 1970	Ala	<i>European Biotechnology Crossroads presents international conference programme 7th European Biotech Crossroads presents international</i>
Aptanomics and Nanosyn collaborate to discover new cancer drugs	1st January, 1970	Aptanomics	<i>Aptanomics and Nanosyn collaborate to discover new cancer drugs Nanosyn and Aptanomics combine their expertise in high quality chemistry and proprietary peptide aptamer</i>

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

